Overview

This bill significantly expands the federal government's commitment to procuring and promoting biobased products through amendments to the Biobased Markets Program under the Farm Security and Rural Investment Act of 2002. The legislation aims to boost the U.S. biomanufacturing and biorefining industries by mandating increased federal purchases of biobased products, enhancing reporting and transparency, and providing price preferences for these products in federal contracts. Key objectives include updating federal procurement catalogs, establishing annual quotas for biobased purchases by agencies, implementing comprehensive reporting mechanisms, and requiring staff training to drive compliance.

Core Provisions

The bill introduces several major amendments to existing law, focusing on expanding federal procurement of biobased products. It requires federal procurement catalogs to clearly identify eligible biobased products within two years of enactment [§(a)(2)(E)]. Agencies must comply with new procurement requirements for biobased products, including annual updates to increase required quantities [§(a)(2)(A)(i)(IV)]. The legislation mandates annual public reporting on biobased product procurement by agencies [§(a)(2)(F)] and establishes price preferences for these products in federal procurement [§(a)(3)(B)(ix)]. Additionally, it directs agencies to promote U.S.-produced biobased products [§(a)(3)(B)(i)(viii)] and requires training for procurement staff on biobased products within two years [§(a)(4)(D)].

Key Points

• Update federal catalogs to identify biobased products within 2 years
• Establish increasing annual quotas for biobased purchases by agencies
• Mandate annual public reporting on biobased product procurement
• Provide price preferences for biobased products in federal contracts
• Require training for procurement staff within 2 years

Legal References

• Farm Security and Rural Investment Act of 2002, §9002
• Buy American Act
• Title 41, Chapter 83, United States Code

Implementation

The bill assigns implementation responsibilities to several federal entities. The Administrator of General Services is tasked with updating federal catalogs within two years to clearly identify eligible biobased products [§(a)(2)(E)]. The Office of Federal Procurement Policy is responsible for collecting and publishing annual agency reporting on biobased product procurement [§(a)(2)(F)(i)]. Federal agencies are required to annually verify compliance with the biobased procurement program [§(a)(2)(F)(ii)]. The Comptroller General must submit a report to Congress within two years of enactment, assessing agency compliance, guidelines, data adequacy, and providing recommendations [§(a)(4)(n)]. While the bill establishes these implementation mechanisms, it does not specify funding sources for these activities.

Impact

The primary beneficiaries of this legislation are U.S. biobased product manufacturers and the biorefining industry, as the bill aims to significantly increase federal procurement of their products. Federal agencies will face increased administrative burdens due to new procurement requirements, reporting obligations, and staff training mandates. The bill is expected to drive growth in the biobased product market and potentially create jobs in related industries. However, agencies may face challenges in meeting procurement quotas and price preferences, particularly if biobased product availability or cost-competitiveness is limited. The legislation does not specify sunset provisions, suggesting these changes are intended to be permanent alterations to federal procurement practices.

Legal Framework

This bill amends the Biobased Markets Program under the Farm Security and Rural Investment Act of 2002, expanding its scope and requirements. It operates within the federal government's procurement authority and spending power. The legislation interacts with existing procurement laws, including references to the Buy American Act for price preferences [§(a)(3)(B)(ix)] and procurement requirements under Title 41, Chapter 83 of the United States Code [§(a)(2)(A)(i)(IV)]. While the bill enhances federal procurement requirements, it does not appear to preempt state or local laws. The legislation does not explicitly address judicial review provisions, leaving potential challenges to be addressed through existing administrative and judicial processes governing federal procurement.

Critical Issues

Several critical issues arise from this legislation. Implementation challenges may include difficulties in accurately tracking and reporting biobased product procurement across all federal agencies, as well as ensuring adequate training for procurement staff within the two-year timeline. There may be significant cost implications if biobased products are consistently more expensive than alternatives, even with price preferences. Unintended consequences could include market distortions or supply chain disruptions if federal demand outpaces the biobased product industry's capacity to scale up production. Opposition arguments might focus on the potential for increased costs to taxpayers, the administrative burden on federal agencies, and questions about the environmental impact of rapidly scaling up biobased product manufacturing. Additionally, there may be concerns about the bill's impact on non-biobased product industries that currently supply the federal government.